iProcess Global Research Inc. is a leading global provider of biospecimens and laboratory services, with over 20 years of experience and a global network of over 1500 sites. | iProcess Global Research Inc. is a leading global provider of high-quality human biospecimens and comprehensive laboratory services, dedicated to empowering scientific research and accelerating medical breakthroughs. With more than 22 years of experience supporting the life sciences, pharmaceutical, biotechnology, and diagnostic industries, iProcess connects researchers to ethically sourced, clinically annotated human biospecimens through a robust network of 1,500+ pre-qualified clinical sites across over 30+ countries. Built on a foundation of strict regulatory compliance and quality excellence—including ISO 20387 and CAP/CLIA-aligned workflows—iProcess offers end-to-end solutions ranging from customized specimen collection and validated cold-chain logistics to advanced, AI-enhanced laboratory analysis and project management support. iProcess’s global biorepository and laboratory ecosystem provides seamless access to a broad range of human sample types and disease cohorts, enabling organizations to navigate complex research requirements with reliability, flexibility, and scientific integrity. Whether supporting clinical trial biospecimen procurement or delivering integrated lab services, iProcess is committed to advancing research and delivering data researchers can trust. As part of its continued expansion in laboratory services, iProcess is launching AxisOne.ai in February 2026—an AI-powered global R&D platform designed to connect organizations with world-class laboratories and research capabilities worldwide. AxisOne leverages artificial intelligence and deep analytics to accelerate feasibility, optimize lab selection, and streamline execution for specialized testing needs by bringing hundreds of labs and research sites onto a single intelligent platform.
Instant NanoBiosensors Co. Ltd
Instant NanoBiosensors (INB) is an innovative precision medicine company specializing in ultra-sensitive protein-based blood tests for Alzheimer’s disease and gene-based solutions for leukemia through its INLab NGS Solution. Revolutionizing Alzheimer’s Diagnostics Leveraging our proprietary Fiber Optic Particle Plasmon Resonance (FOPPR™) technology, we provide a non-invasive, rapid, and cost-effective solution for the early detection of Alzheimer’s-related biomarkers. Our technology enhances diagnostic accuracy, accelerates drug development, and supports personalized medicine applications for medical institutions and pharmaceutical companies. INB is the only point-of-care testing (POCT) platform on the market that enables end-to-end solutions—from antibody analysis to ultra-sensitive assay development. This platform has been adopted by the EU-funded TAuimMunE (TAME) project as a key training tool for PhD researchers. Current blood biomarker diagnostic methods are often expensive, centralized, and require specialized personnel to operate. INB’s solution addresses these limitations by making early Alzheimer’s detection more accessible and affordable. Our goal is to provide a highly accessible and precise diagnostic platform that enhances patient care and therapeutic outcomes worldwide. Leukemia Precision Medicine: INLab NGS Solution In leukemia diagnostics, INB has developed a comprehensive NGS Precision Medicine Solution that streamlines the entire workflow—from sample processing to final report generation—with fully integrated instruments, reagents, and software. We have extensive experience collaborating with National Taiwan University Hospital, working closely with hematology and oncology specialists to develop clinically relevant diagnostic reagents. Our solution currently serves nearly 70% of leukemia patients in Taiwan and has also been adopted by Yale Medical Center in the United States. Key Advantages of Our Solution ✅ Enhanced Accuracy and Efficiency: Our proprietary DimerOff™ technology minimizes primer dimer formation and sequencing noise, producing cleaner, more accurate sequencing data. This significantly improves sensitivity for detecting MDS/AML-related mutations, ensures higher clinical reliability, reduces sequencing costs by more than 50%, and shortens the turnaround time to just three days. ✅ MRD Detection & MPN Monitoring: Our solution enables precise monitoring of measurable residual disease (MRD) and myeloproliferative neoplasms (MPN), supporting long-term patient management and treatment adjustments. ✅ Customizable Panels for Specific Clinical Needs: We work closely with clinicians and researchers to develop NGS panels tailored to specific research and diagnostic requirements. Our flexible approach optimizes mutation detection, enhances patient stratification, and reduces operational costs for both research and clinical applications. Through continuous innovation and strategic partnerships, INB is committed to transforming precision medicine and improving patient outcomes worldwide. We Are Seeking Partnerships With: International Distributors interested in bringing our innovative diagnostic solutions to global markets. Biotech Companies looking for co-development opportunities in assay and panel development. Pharmaceutical Companies seeking companion diagnostics solutions to support targeted drug development. Hospitals & CROs aiming to establish a comprehensive precision medicine system within their organization. Scientists & Research Institutions interested in collaborative grant applications. If you are interested in collaborating with us, we welcome the opportunity to discuss how INB’s cutting-edge solutions can support your research, clinical, and commercial objectives.
HiComp
Established in 2014, HiComp Microtech stands as a premier original design manufacturer specializing in advanced microfluidics products and laboratory consumables. Our solutions boost precision, efficiency, and reliability from prototyping to mass production. Quality, performance and affordability are our priorities. | Established in 2014, HiComp Microtech is a leading original design manufacturer (ODM) specializing in advanced microfluidic products and laboratory consumables. Our ISO-certified and FDA-registered facilities span 100,000 sq. ft., including approximately 40,000 sq. ft. of high-standard cleanroom space. We provide precision, efficiency, and reliability from prototyping through volume production, serving renowned pharmaceutical and clinical diagnostic companies globally. With a proven track record, HiComp has successfully completed over 100 commercialized projects. Our services include: • Product Design • 3D Printing • CNC Micro Milling • MEMS Manufacturing • PDMS Manufacturing • Organoids/Organ on a Chip • Cleanroom Injection Molding • Surface Functionalization • Bonding & Sealing • Custom Microwell Plates • Assembly & Automation • Reagent Storage and Lyophilization
Cleveland Clinic Innovations
We are more than a tech transfer office. We are a medical innovations powerhouse. Cleveland Clinic Innovations brings the best ideas from the brightest minds in medicine to patients around the world. We connect inventors and their ideas with strategic industry partners to create products that transform the future of healthcare. Cleveland Clinic is changing healthcare for patients around the world. https://39682636.hs-sites.com/bio-home | x | Cleveland Clinic Innovations (CCI) is dedicated to turning caregiver-inspired ideas into medical breakthroughs that meaningfully improve patient lives. Since 2000, our team has transformed over 900 technologies into licensed products, secured more than 2,800 patents, and launched over 100 spin-off companies, achieving 28 successful exits. Our multidisciplinary team works side-by-side with clinicians, researchers, and industry to guide innovations through every stage, from concept to licensing, startup formation, clinical validation, and scaling. We’re more than a technology transfer office, we’re strategic partners in transforming healthcare innovation. Whether it’s harnessing AI for diagnostics, pioneering digital health solutions, developing novel therapeutics, or creating advanced drug delivery systems, we ensure that innovative ideas become practical solutions impacting patient care globally. Technologies available for licensing include: · Digital Health · Drug Delivery · Diagnostics · Therapeutics · Research Tools What Makes Cleveland Clinic Innovations Unique? · Direct clinician and researcher access for rapid, real-world healthcare insights. · Robust clinical validation and real-world data-driven innovation within a globally recognized health system. · Comprehensive IP management, strategic licensing expertise, and proven healthcare startup incubation. Why partner with Cleveland Clinic Innovations? · Expert guidance through healthcare startup creation, technology transfer, and commercialization pathways. · Integrated access to world-class clinical, regulatory, and research infrastructure. · Global presence supporting innovations across markets (U.S., London, Abu Dhabi, Canada). Together, we can accelerate healthcare innovation and create meaningful patient impact. Explore our technologies and partner with us: https://my.clevelandclinic.org/innovations
CheckImmune GmbH
CheckImmune is an innovative immune biomarker CRO for preclinical and clinical programs. As a spin-off company of Charité Universitätsmedizin Berlin we have strong links to academic state-of-the art research. CheckImmune is providing biomarker studies with focus on novel immunotherapeutics (small molecules, biologics, Advanced Therapy Medicinal Products – ATMPs) and immunological challenges in other medical areas. CheckImmune is specialized in the development and validation of immunological biomarkers for global clinical trials and accredited according to ISO 17025 and 15189 with fulfilling the requirements of GCLP (Good Clinical Laboratory Practice). Our core expertise includes assay development and validation for Receptor Occupancy, Flow Cytometry, Multiplex Cytokine Analyses, Functional Tests, Single Cell Multiomics, and Tissue Biopsies. We are a certified service provider for 10x Genomics, Olink, and ProteinSimple Ella. We are a team of well recognized experts for immune biomarker analyses and data interpretation. Our Services are Selection/validation of drug lead candidates, Phase 0 studies with access to fresh patient material, Therapy monitoring (safety, efficacy/stratification) and Data analysis and scientific & medical interpretation. At CheckImmune, we develop highly specialized immunological biomarker assays and provide end-to-end lab services for clinical and preclinical trials. From assay design to regulatory-grade data analysis – we help biopharma companies understand immune responses with precision. We are a certified service provider for 10x Genomics, OLINK and bio-techne. With a track record of more than 90 industry-sponsored trials and 120,000 samples we have earned an excellent international reputation. Selection/validation of drug lead candidates Application of a broad panel of customized and off-the-shelf biomarker tests using cutting-edge technologies for lead candidate selection. Phase 0 studies with access to fresh patient material Proof-of-concept studies on biosamples from target patient populations (phase 0) to develop and confirm selected biomarker test portfolios for following therapy monitoring. Therapy monitoring Therapy monitoring in clinical trials to check safety, PD/PK, patient stratification with a wide range of validated assays as well as newly developed customized methods. Data analysis and scientific & medical interpretation CheckImmune is backed by a world-renowned team of experts with years of academic and commercial experience in the field of immune biomarkers. Technology used Our Technology platforms are – Complex Flow & Spectral Cytometry – Molecular & Multi-Omics Analysis: Bulk RNAseq, TCR /BCR repertoire, Single cell Multiomics (RNAseq, TCRseq, CITEseq) Spatial multi-omics, qRT- PCR (e.g. IFN signature) and digitalPCR – Multiplex Ligand Assays (MSD, Ella, OLINK) – Functional Assays – Anti-Drug Response (ADA/ADT)
BloodScan Biotech Inc.
BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.